11 – 20 of 39
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Measurable residual disease testing for personalized treatment of acute myeloid leukemia
(
- Contribution to journal › Scientific review
-
Mark
Hif-1α Deletion May Lead to Adverse Treatment Effect in a Mouse Model of MLL-AF9-Driven AML
(
- Contribution to journal › Article
-
Mark
Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML
(
- Contribution to journal › Article
-
Mark
The role of SRC family kinases in FLT3 signaling
(
- Contribution to journal › Scientific review
- 2018
-
Mark
DNA and RNA binding by the Wilms' tumour gene 1 (WT1) protein +KTS and −KTS isoforms—From initial observations to recent global genomic analyses
(
- Contribution to journal › Scientific review
-
Mark
Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation
(
- Contribution to journal › Article
-
Mark
Identification of intrinsic regulators in normal and malignant human hematopoiesis. An RNA-interference approach.
(
- Thesis › Doctoral thesis (compilation)
- 2017
-
Mark
Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing
(
- Contribution to journal › Article
-
Mark
Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms' tumor gene 1 (WT1) protein in leukemic cells
(
- Contribution to journal › Article
-
Mark
Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD
(
- Contribution to journal › Article